Anti-glaucoma drugs

Blacker, A. J., Holt, R. A. Development of a Multi-stage Chemical and Biological Process for an Optically Active Intermediate for an Anti-glaucoma Drug. In Chirality in Industry II, Collins, A. N., Sheldrake, G. N., Crosby, J. Eds., John Wiley Sons Chichester, 1997, p. 245. 

Stjernschantz et al. later developed latanoprost [22], which has potent IOP-reducing effects with topical administration once daily in the evening. Compared with a representative (3-blocker, timolol, it demonstrated superior efficacy in clinical studies in reducing IOP by approximately 27-34% from baseline. Latanoprost is the FP receptor agonist most widely used worldwide as an anti-glaucoma drug. 

Fluprostenol was marketed in form of its racemate by ICI as a contraceptive in the veterinary sector. The synthetic route developed for this product proceeds via the Corey lactone, whereby the side-chains are built up using Horner-Wadsworth-Emmons or Wittig reactions. Travoprost, the enantio-merically pure isopropyl ester of fluprostenol, is a potent anti-glaucoma drug, for which Chirotech Technology Ltd. has published an interesting synthesis (Fig. 5.102). [229]... 

Glaucoma is a disorder of vision accompanied by an increase in ocular pressure. Although mostly replaced by other drugs (e.g., beta blockers and pilocarpine), anti-ChE drugs such as ecothiopate are still used in the treatment of these common disorders. 

---